{"id":"ethinylestradiol-levonorgestrel","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Breast tenderness"},{"rate":"5-15","effect":"Breakthrough bleeding"},{"rate":"0.3-0.4","effect":"Venous thromboembolism"},{"rate":"2-5","effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ethinylestradiol is a synthetic estrogen and levonorgestrel is a synthetic progestin. Together, they provide negative feedback to the hypothalamic-pituitary-ovarian axis, preventing follicle-stimulating hormone (FSH) and LH secretion. This dual hormonal action prevents ovulation, thickens cervical mucus to impede sperm transport, and alters the endometrium to reduce implantation likelihood.","oneSentence":"Ethinylestradiol/levonorgestrel is a combined oral contraceptive that suppresses ovulation by inhibiting gonadotropin-releasing hormone (GnRH) and preventing the luteinizing hormone (LH) surge required for egg release.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:49.501Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception / prevention of pregnancy"},{"name":"Regulation of menstrual cycles"}]},"trialDetails":[{"nctId":"NCT06513104","phase":"PHASE1","title":"A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-07-18","conditions":"Diabetes Mellitus, Type 2","enrollment":47},{"nctId":"NCT07013643","phase":"PHASE1","title":"A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-04","conditions":"Healthy Participants","enrollment":75},{"nctId":"NCT07074327","phase":"PHASE1","title":"Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-07-11","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":74},{"nctId":"NCT07229209","phase":"NA","title":"Oral Contraceptive Pills Versus Levonorgestrel-Releasing Intrauterine System for Niche-Related Abnormal Uterine Bleeding","status":"COMPLETED","sponsor":"Benha University","startDate":"2025-02-05","conditions":"Abnormal Uterine Bleeding, Cesarean Section Complications, Uterine Scar","enrollment":166},{"nctId":"NCT07288190","phase":"PHASE2","title":"Phase 2b, Open Label, Multisite, Randomized Crossover Study of DPP Versus 2PR","status":"NOT_YET_RECRUITING","sponsor":"HIV Prevention Trials Network","startDate":"2026-05-15","conditions":"Pregnancy, HIV Infections","enrollment":300},{"nctId":"NCT07414784","phase":"PHASE1","title":"A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives","status":"RECRUITING","sponsor":"AbbVie","startDate":"2026-02-11","conditions":"Healthy Volunteer","enrollment":20},{"nctId":"NCT07388511","phase":"PHASE1","title":"A Study of Elenestinib in Healthy Adult Female Participants","status":"RECRUITING","sponsor":"Blueprint Medicines Corporation","startDate":"2026-02-03","conditions":"Healthy Participants","enrollment":20},{"nctId":"NCT06942936","phase":"PHASE1","title":"A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-05-28","conditions":"Healthy Participants","enrollment":51},{"nctId":"NCT07338955","phase":"","title":"Validating and Assessing Reliability","status":"RECRUITING","sponsor":"Bahria University","startDate":"2025-11-03","conditions":"Upper Limb Disability","enrollment":385},{"nctId":"NCT03043924","phase":"NA","title":"Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS)","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2017-09-26","conditions":"Polycystic Ovary Syndrome","enrollment":52},{"nctId":"NCT07190430","phase":"PHASE1","title":"A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-10-03","conditions":"Atopic Dermatitis","enrollment":16},{"nctId":"NCT07272889","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)","status":"NOT_YET_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-12","conditions":"Healthy Volunteer Study","enrollment":24},{"nctId":"NCT04255277","phase":"PHASE1","title":"To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.","status":"COMPLETED","sponsor":"Viatris Innovation GmbH","startDate":"2020-01-31","conditions":"Healthy Subjects","enrollment":97},{"nctId":"NCT06354257","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-04-05","conditions":"Tuberculosis","enrollment":20},{"nctId":"NCT06186271","phase":"","title":"International Active Surveillance Study: Safety of Estrogen Estetrol (E4) Contraceptive Study (INAS-SEECS)","status":"RECRUITING","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2025-04-24","conditions":"Contraception","enrollment":68100},{"nctId":"NCT06028555","phase":"","title":"International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety Study","status":"RECRUITING","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2023-06-28","conditions":"Contraception, Birth Control","enrollment":101000},{"nctId":"NCT06071442","phase":"PHASE1","title":"Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-01-17","conditions":"Healthy Participants","enrollment":60},{"nctId":"NCT04972396","phase":"PHASE1","title":"Pemvidutide (ALT-801) DDI Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Altimmune, Inc.","startDate":"2021-09-15","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":40},{"nctId":"NCT06461039","phase":"PHASE1","title":"A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-06-14","conditions":"Obesity","enrollment":43},{"nctId":"NCT03249402","phase":"PHASE1","title":"A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2017-08-14","conditions":"Healthy","enrollment":24},{"nctId":"NCT06671405","phase":"PHASE1","title":"An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-09-25","conditions":"Dyslipidaemia","enrollment":59},{"nctId":"NCT03547024","phase":"PHASE1","title":"A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2018-06-08","conditions":"Healthy","enrollment":14},{"nctId":"NCT05896384","phase":"PHASE1","title":"A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2023-12-21","conditions":"Healthy","enrollment":32},{"nctId":"NCT02636972","phase":"","title":"The Progression From Dysmenorrhoea to Chronic Pelvic Pain","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2014-11","conditions":"Dysmenorrhoea, Pelvic Pain, Chronic Pain","enrollment":56},{"nctId":"NCT06799884","phase":"PHASE1","title":"A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2025-01-18","conditions":"Drug Drug Interaction","enrollment":19},{"nctId":"NCT06188026","phase":"PHASE1","title":"A Research Study Looking at How the Compound NNC0194-0499 Works With Birth Control Pills in Women Not Able to Bear Children.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-12-18","conditions":"Healthy Volunteers (Non-alcoholic Steatohepatitis)","enrollment":34},{"nctId":"NCT06657105","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-11-01","conditions":"Healthy Participants","enrollment":22},{"nctId":"NCT06783192","phase":"PHASE1","title":"A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-08-14","conditions":"Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis","enrollment":14},{"nctId":"NCT05058872","phase":"PHASE4","title":"Contraceptive Hormone and Reward Measurement (CHARM Study)","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-10-01","conditions":"Oral Hormonal Contraceptive Use, Neural Activity, Mood","enrollment":144},{"nctId":"NCT03557619","phase":"PHASE1","title":"A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies","status":"RECRUITING","sponsor":"AbbVie","startDate":"2019-07-30","conditions":"Hematologic Malignancies","enrollment":12},{"nctId":"NCT05093205","phase":"PHASE1","title":"STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-10-25","conditions":"Healthy Adults","enrollment":35},{"nctId":"NCT06380205","phase":"PHASE1","title":"A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2024-05-07","conditions":"Healthy Participants","enrollment":24},{"nctId":"NCT02616146","phase":"PHASE3","title":"Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2015-12-01","conditions":"Contraception","enrollment":2016},{"nctId":"NCT05487092","phase":"NA","title":"Letrozole in Preventing Recurrence of Endometrioma Following Laparoscopic Ovarian Cystectomy","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2022-12-01","conditions":"Endometriotic Cyst of Ovary","enrollment":194},{"nctId":"NCT03745144","phase":"PHASE1","title":"Effects of Cladribine Tablets on the PK of Microgynon®","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2019-01-17","conditions":"Relapsing Multiple Sclerosis (RMS)","enrollment":28},{"nctId":"NCT03193307","phase":"PHASE1","title":"This Study Tests in Healthy Korean Women Which Effects BI 409306 and a Birth-control Pill Have on Each Other","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-06-29","conditions":"Healthy","enrollment":16},{"nctId":"NCT02828904","phase":"","title":"RIVET - Retrospective Cohort Study on the Risk of Venous Thromboembolism","status":"COMPLETED","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2022-03-10","conditions":"Venous Thromboembolism","enrollment":124000},{"nctId":"NCT04778514","phase":"NA","title":"A Crossover Acceptability Study Assessing a DPP Capsule for HIV and Pregnancy Prevention","status":"COMPLETED","sponsor":"Population Council","startDate":"2022-12-07","conditions":"HIV Infections, Contraception","enrollment":30},{"nctId":"NCT04007874","phase":"PHASE3","title":"Oral Contraceptive Pill Compared With Vitamin E in Women With Migraine","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2019-09-10","conditions":"Migraine, Migraine;Menstrual","enrollment":360},{"nctId":"NCT05153564","phase":"PHASE1","title":"A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-12-13","conditions":"Diabetes Mellitus, Type 2","enrollment":27},{"nctId":"NCT05613777","phase":"PHASE1","title":"A Study in Healthy Women to Test Whether BI 425809 Influences the Amount of a Contraceptive in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-11-24","conditions":"Healthy","enrollment":19},{"nctId":"NCT03074045","phase":"PHASE3","title":"LCS16 vs. COC User Satisfaction and Tolerability Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-03-13","conditions":"Contraception","enrollment":145},{"nctId":"NCT03954366","phase":"PHASE1","title":"Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2019-04-25","conditions":"Neoplasms","enrollment":36},{"nctId":"NCT04423068","phase":"EARLY_PHASE1","title":"Inpatient Adolescent Contraception","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2020-12-10","conditions":"Pregnancy Related, Contraception, Contraceptive Usage","enrollment":25},{"nctId":"NCT05505162","phase":"PHASE1","title":"Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-08-24","conditions":"Healthy Female Participants","enrollment":24},{"nctId":"NCT05594186","phase":"NA","title":"Nonsurgical Management of Cesarean Scar Niche Related Abnormal Uterine Bleeding","status":"COMPLETED","sponsor":"Saudi German Hospital - Madinah","startDate":"2019-03-01","conditions":"Intermenstrual Bleeding","enrollment":158},{"nctId":"NCT05282940","phase":"PHASE1","title":"Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product","status":"COMPLETED","sponsor":"Laboratorios Andromaco S.A.","startDate":"2022-02-26","conditions":"Therapeutic Equivalency","enrollment":36},{"nctId":"NCT05212389","phase":"NA","title":"The Pill Project - Oral Contraceptive and Serotonergic Brain Signaling","status":"UNKNOWN","sponsor":"Rigshospitalet, Denmark","startDate":"2021-12-22","conditions":"Major Depressive Disorder, Sexual Behavior, Mood Disturbance","enrollment":40},{"nctId":"NCT00511355","phase":"PHASE3","title":"Effects on Hemostasis, Lipids, Carbohydrate Metabolism, Adrenal & Thyroid Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG-EE (292004)(COMPLETED)(P05764)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-10","conditions":"Contraception","enrollment":121},{"nctId":"NCT00511342","phase":"PHASE3","title":"Effects on Bone Mineral Density (BMD) of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG/EE (292005)(P05765)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Contraception","enrollment":110},{"nctId":"NCT01044056","phase":"PHASE4","title":"A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) (Study 34237 (P06650)) (COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-03","conditions":"Contraception","enrollment":24},{"nctId":"NCT03709355","phase":"PHASE1","title":"Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs","status":"COMPLETED","sponsor":"Viriom","startDate":"2018-11-14","conditions":"HIV-1-infection","enrollment":56},{"nctId":"NCT04074174","phase":"PHASE1","title":"Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become Pregnant","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-09-12","conditions":"Overweight, Obesity","enrollment":31},{"nctId":"NCT01873170","phase":"","title":"Quantification of Immune Cells in Women Using Contraception (CHIC II)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2013-08","conditions":"HIV, Immune Cells (Mucosal and Systemic), Contraception","enrollment":326},{"nctId":"NCT01291004","phase":"PHASE1","title":"A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2011-01-31","conditions":"Follicle Development, Ovarian Follicle, Follicle Count","enrollment":206},{"nctId":"NCT05116371","phase":"","title":"Control of Bleeding on Nexplanon in Latinx Patients","status":"UNKNOWN","sponsor":"University of Arizona","startDate":"2021-12-01","conditions":"Contraception","enrollment":144},{"nctId":"NCT02085863","phase":"PHASE1","title":"A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod on Standard Oral Contraceptive When Both Treatments Are Given Together","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-02","conditions":"Pharmacokinetics, Pharmacodynamics","enrollment":40},{"nctId":"NCT00447863","phase":"PHASE1","title":"Study Evaluating the Bioequivalence of Levonorgestrel/Ethinyl Estradiol Combinations in Cycling Women","status":"WITHDRAWN","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-08","conditions":"Contraception","enrollment":""},{"nctId":"NCT02002260","phase":"NA","title":"Stopping Heavy Periods Project","status":"UNKNOWN","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2013-02","conditions":"Abnormal Uterine Bleeding, Abnormal Uterine Bleeding, Ovulatory Dysfunction, Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction","enrollment":59},{"nctId":"NCT04131517","phase":"PHASE1","title":"A Study to Test the Interaction of Padsevonil With Oral Contraceptives in Healthy Female Participants","status":"TERMINATED","sponsor":"UCB Biopharma SRL","startDate":"2019-10-23","conditions":"Healthy Female Participants","enrollment":14},{"nctId":"NCT04194905","phase":"PHASE1","title":"Bioavailability of Levonorgestrel/Ethinyl Estradiol Tablets 0.1 mg/0.02 mg With Regards to Reference Product","status":"COMPLETED","sponsor":"Laboratorios Andromaco S.A.","startDate":"2020-11-21","conditions":"Bioequivalence","enrollment":10},{"nctId":"NCT04230070","phase":"PHASE1","title":"Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product","status":"COMPLETED","sponsor":"Laboratorios Andromaco S.A.","startDate":"2020-10-24","conditions":"Bioequivalence","enrollment":30},{"nctId":"NCT02556411","phase":"NA","title":"Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS)","status":"UNKNOWN","sponsor":"University of Cagliari","startDate":"2021-06-01","conditions":"Adenomyosis, Chronic Pelvic Pain","enrollment":50},{"nctId":"NCT02577913","phase":"","title":"European Active Surveillance Study Comparing Regimens of Administration in Combined Hormonal Contraception","status":"TERMINATED","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2015-11","conditions":"Contraception","enrollment":2281},{"nctId":"NCT04267250","phase":"PHASE1","title":"Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-08-24","conditions":"Healthy Female Volunteers","enrollment":18},{"nctId":"NCT03675581","phase":"PHASE1","title":"A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-11-08","conditions":"Scleroderma, Systemic","enrollment":17},{"nctId":"NCT00662454","phase":"PHASE4","title":"Oral Contraceptive Efficacy and Body Weight","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2006-01","conditions":"Contraception, Body Weight","enrollment":120},{"nctId":"NCT03984825","phase":"PHASE1","title":"Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-06-13","conditions":"HIV Infections","enrollment":23},{"nctId":"NCT01805817","phase":"PHASE4","title":"Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality","status":"WITHDRAWN","sponsor":"Istanbul Training and Research Hospital","startDate":"2012-12","conditions":"Contraceptive Methods Comparison","enrollment":""},{"nctId":"NCT04309643","phase":"PHASE1","title":"Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects","status":"COMPLETED","sponsor":"Concert Pharmaceuticals","startDate":"2020-06-09","conditions":"Healthy Volunteers","enrollment":21},{"nctId":"NCT02158572","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery System","status":"COMPLETED","sponsor":"Agile Therapeutics","startDate":"2014-08","conditions":"Healthy","enrollment":2032},{"nctId":"NCT03353857","phase":"PHASE1","title":"Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-11-29","conditions":"Biological Availability","enrollment":68},{"nctId":"NCT03662516","phase":"PHASE1","title":"A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-09-26","conditions":"Healthy Females","enrollment":17},{"nctId":"NCT04142762","phase":"PHASE1","title":"A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2019-10-18","conditions":"Chronic Hepatitis B","enrollment":80},{"nctId":"NCT03301207","phase":"PHASE1","title":"A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-10-20","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":25},{"nctId":"NCT04018274","phase":"PHASE1","title":"Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-08-09","conditions":"Healthy","enrollment":29},{"nctId":"NCT02577601","phase":"PHASE4","title":"Impact of Combined Hormonal Contraceptives on UPA","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2015-09-08","conditions":"Contraception","enrollment":36},{"nctId":"NCT02531321","phase":"PHASE4","title":"Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2015-08","conditions":"Contraception, HIV","enrollment":17},{"nctId":"NCT00827632","phase":"PHASE4","title":"Obesity, Oral Contraception, and Ovarian Suppression","status":"COMPLETED","sponsor":"Columbia University","startDate":"2006-07","conditions":"Ovarian Suppression","enrollment":226},{"nctId":"NCT02362711","phase":"PHASE3","title":"Efficacy and Safety, Long-Term Study of NPC-16 to Treat Dysmenorrhea","status":"COMPLETED","sponsor":"Nobelpharma","startDate":"2015-02","conditions":"Dysmenorrhea","enrollment":248},{"nctId":"NCT02751385","phase":"PHASE1","title":"Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2016-05-20","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":2},{"nctId":"NCT03210246","phase":"PHASE1","title":"Drug-drug Interaction Study: Influence of Vilaprisan on Pharmacodynamics (PD) and Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-07-17","conditions":"Clinical Trial ,Phase I","enrollment":71},{"nctId":"NCT02404038","phase":"NA","title":"A Study to Evaluate the Acceptability and Preference for Contraceptive Options as Proxy for HIV Prevention Methods","status":"UNKNOWN","sponsor":"Desmond Tutu HIV Centre","startDate":"2015-07","conditions":"HIV","enrollment":131},{"nctId":"NCT01422135","phase":"PHASE1","title":"Pharmacokinetic Study of AG200-15 Transdermal Patch to Three Anatomical Sites in Healthy Females","status":"COMPLETED","sponsor":"Agile Therapeutics","startDate":"2011-02","conditions":"Healthy","enrollment":24},{"nctId":"NCT03324685","phase":"PHASE1","title":"A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen","status":"COMPLETED","sponsor":"Biogen","startDate":"2017-11-11","conditions":"Drug Interactions","enrollment":36},{"nctId":"NCT01250210","phase":"PHASE2","title":"Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control","status":"COMPLETED","sponsor":"Agile Therapeutics","startDate":"2007-09","conditions":"Ovulation Suppression","enrollment":123},{"nctId":"NCT01181479","phase":"PHASE3","title":"Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System","status":"COMPLETED","sponsor":"Agile Therapeutics","startDate":"2010-08","conditions":"Contraception","enrollment":1504},{"nctId":"NCT03506399","phase":"PHASE1","title":"A Study of Lanabecestat in Healthy Female Participants Taking Oral Contraceptive","status":"WITHDRAWN","sponsor":"Eli Lilly and Company","startDate":"2018-06","conditions":"Healthy","enrollment":""},{"nctId":"NCT03478020","phase":"PHASE1","title":"Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study","status":"COMPLETED","sponsor":"Aquinox Pharmaceuticals (Canada) Inc.","startDate":"2017-11-22","conditions":"Healthy Volunteer","enrollment":32},{"nctId":"NCT02846142","phase":"PHASE1","title":"Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers","status":"COMPLETED","sponsor":"Proteostasis Therapeutics, Inc.","startDate":"2016-06","conditions":"Healthy Volunteer","enrollment":94},{"nctId":"NCT00310791","phase":"PHASE2, PHASE3","title":"Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2004-04","conditions":"Anorexia Nervosa","enrollment":80},{"nctId":"NCT01941134","phase":"PHASE4","title":"Changes in Oral Contraceptive Hormones After Gastric Bypass Surgery","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2013-04","conditions":"Bariatric Surgery Candidate, Contraception","enrollment":""},{"nctId":"NCT02957630","phase":"PHASE1, PHASE2","title":"\"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study\"","status":"COMPLETED","sponsor":"Estetra","startDate":"2016-09","conditions":"Contraception, Liver Metabolism, Hemostasis Parameter","enrollment":101},{"nctId":"NCT01243580","phase":"PHASE1","title":"AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol","status":"COMPLETED","sponsor":"Agile Therapeutics","startDate":"2009-08","conditions":"Healthy","enrollment":36},{"nctId":"NCT02697851","phase":"PHASE1","title":"Pharmacokinetic Effect of Evotaz/Microgynon Co-administration","status":"TERMINATED","sponsor":"St Stephens Aids Trust","startDate":"2016-07","conditions":"HIV","enrollment":13},{"nctId":"NCT03359057","phase":"PHASE3","title":"Trial Evaluating Folic Acid Supplementation by Concomitant Administration of Ethinyl Estradiol + Levonorgestrel","status":"COMPLETED","sponsor":"Galeno Desenvolvimento de Pesquisas Clínicas","startDate":"2013-02-26","conditions":"Contraception","enrollment":36},{"nctId":"NCT01254292","phase":"PHASE3","title":"LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-01-06","conditions":"Contraception","enrollment":567},{"nctId":"NCT01236768","phase":"PHASE3","title":"Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm","status":"COMPLETED","sponsor":"Agile Therapeutics","startDate":"2010-10","conditions":"Contraception","enrollment":407},{"nctId":"NCT00213096","phase":"PHASE2","title":"Effects of Hormonal Contraceptives on Liver Proteins and Coagulation Factors: A Comparison of a Contraceptive Vaginal Ring and an Oral Contraceptive","status":"COMPLETED","sponsor":"Population Council","startDate":"2003-03","conditions":"Contraception","enrollment":50},{"nctId":"NCT00483535","phase":"PHASE1","title":"Oral Contraceptive Interaction Study for GW273225","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2007-03-07","conditions":"Bipolar Disorder","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":56,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Microgynon 30","RVG 08204"],"phase":"phase_3","status":"active","brandName":"Ethinylestradiol/levonorgestrel","genericName":"Ethinylestradiol/levonorgestrel","companyName":"Leiden University Medical Center","companyId":"leiden-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ethinylestradiol/levonorgestrel is a combined oral contraceptive that suppresses ovulation by inhibiting gonadotropin-releasing hormone (GnRH) and preventing the luteinizing hormone (LH) surge required for egg release. Used for Contraception / prevention of pregnancy, Regulation of menstrual cycles.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}